论文部分内容阅读
本研究抽取笔者所在医院2014年4月~2015年6月接受治疗的82例尿毒症患者为研究对象,随机分成观察组与对照组,每组41例。在治疗3个月后,对比两组的生化指标,包括血肌酐(Cr)、尿素氮(BUN)、血白蛋白(ALB)、β2-微球蛋白(β2-MG),以及SF-36量表评分结果。结果在观察组的SF-36量表中显示,总有效率为92.68%,而对照组总有效率为68.29%,具有显著差异(P<0.05)。临床上应用高通量血液透析对尿毒症患者有较高的安全性,疗效确切且能提高患者生存水平,值得深入研究并推广。
In this study, 82 patients with uremia treated in our hospital from April 2014 to June 2015 were selected as study subjects and randomly divided into observation group and control group with 41 cases in each group. After 3 months of treatment, the biochemical parameters including serum creatinine (Cr), blood urea nitrogen (BUN), albumin (ALB), β2-microglobulin (β2-MG) Table score results. Results In the SF-36 scale of the observation group, the total effective rate was 92.68%, while the total effective rate was 68.29% in the control group, with significant difference (P <0.05). Clinical application of high-throughput hemodialysis in patients with uremia have a higher safety, efficacy and can improve the patient’s survival level, it is worth further study and promotion.